PRACTICAL ONCOLOGY JOURNAL ›› 2013, Vol. 27 ›› Issue (5): 447-451.doi: 10.3969/j.issn.1002-3070.2013.05.016

• Review • Previous Articles     Next Articles

Advance of transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma

WANG Fa,WANG Honghui   

  1. Department of International Radiology,The Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China
  • Received:2013-04-10 Online:2013-10-28 Published:2013-10-15

Abstract: Primary liver cancer is a common malignancy worldwide.Early detection and early treatment of liver cancer has become the focus of clinical research.Radiofrequency ablation(RFA)at home and abroad has been recognized as an effective treatment for small hepatocellular carcinoma,especially for the small diameter of less than 3cm in patients with liver cancer.The cure rate has reached or even exceeded surgical resection.Diameter greater than 3cm in the treatment of small hepatocellular carcinoma in patients treated with RFA single recurrence rate is relatively high.Transcatheter arterial chemoembolization (TACE) for the treatment of liver cancer has long been recognized,but there are also some disadvantages.After TACE,the original artery system is changed,easy to set up collateral circulation,focal necrosis rate is low,the recurrence rate is high,and repeated TACE treatment will increase the liver function damage.TACE combined with the RAF in the treatment of small hepatocellular carcinoma in patients with each other,improve treatment safety,efficacy,and long-term outcome for patients.This paper studies the TACE combined RFA of small hepatocellular carcinoma status and progress.

CLC Number: